Lightlake Therapeutics Inc (LLTP)
-OTC Markets 0.04 
0.00(2.44%) 2:51PM EDT
| Prev Close: | 0.04 |
|---|
| Open: | 0.04 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 6.35 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.04 - 0.04 |
|---|
| 52wk Range: | 0.03 - 0.20 |
|---|
| Volume: | 88,800 |
|---|
| Avg Vol (3m): | 337,403 |
|---|
| Market Cap: | 5.58M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements aEDGAR Online(Wed, May 8)
- Lightlake Therapeutics Inc. to Develop Opioid Drug Treatment in Collaboration with the National Institute on Drug Abuse (NIDA)Business Wire(Wed, Apr 24)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 24)
- Lightlake Therapeutics Inc. Provides Guidance on Company OperationsBusiness Wire(Thu, Apr 4)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Thu, Apr 4)
- Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual MeetingBusiness Wire(Wed, Mar 27)
- LIGHTLAKE THERAPEUTICS INC. FinancialsEDGAR Online Financials(Fri, Mar 22)
- The Daily Startup: Valuations for Later-Stage Rounds Hit Post-Bubble Highsat The Wall Street Journal(Thu, Mar 21)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Mar 18)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Wed, Jan 30)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements aEDGAR Online(Tue, Jan 22)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Dec 20)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, Nov 27)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Nov 8)
- LIGHTLAKE THERAPEUTICS INC. Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Oct 29)
Reports
- No Reports available for LLTP at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Lightlake Therapeutics, Inc., an early stage biopharmaceutical company, focuses on developing a treatment for overweight and obese patients with binge eating disorders.
View More